| Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress |
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on the company's PK activators, mitapivat and tebapivat, will be featured in oral and poster presentations during the 30th European Hematology Association (EHA) Congress (EHA 2025) in Milan, Italy, June 12-15, 2025. |
globenewswire.com |
2025-05-14 14:00:00 |
Czytaj oryginał (ang.) |
| Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 |
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 8:00 am ET. |
globenewswire.com |
2025-05-09 11:00:00 |
Czytaj oryginał (ang.) |
| Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates |
AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same. |
zacks.com |
2025-05-02 12:55:36 |
Czytaj oryginał (ang.) |
| Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 |
CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 8:00 am PT/11:00 am ET. |
globenewswire.com |
2025-05-02 11:00:00 |
Czytaj oryginał (ang.) |
| Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript |
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Chris Taylor – Vice President-Investor Relations and Corporate Communications Brian Goff – Chief Executive Officer Sarah Gheuens – Chief Medical Officer, Head-Research and Development Tsveta Milanova – Chief Commercial Officer Cecilia Jones – Chief Financial Officer Conference Call Participants Gregory Renza – RBC Capital Markets Alec Stranahan – Bank of America Divya Rao – TD Cowen Hiro Nagayumi – Cantor Emily Bodnar – H.C. Wainwright Tessa Romero – JPMorgan Operator Good morning, and welcome to Agios' First Quarter 2025 Conference Call. |
seekingalpha.com |
2025-05-01 16:06:43 |
Czytaj oryginał (ang.) |
| Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates |
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.55 per share versus the Zacks Consensus Estimate of a loss of $1.80. This compares to loss of $1.45 per share a year ago. |
zacks.com |
2025-05-01 12:50:40 |
Czytaj oryginał (ang.) |
| Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights |
– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND ® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $1.4 Billion as of March 31, 2025 – CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported business highlights and financial results for the first quarter ended March 31, 2025. |
globenewswire.com |
2025-05-01 10:30:00 |
Czytaj oryginał (ang.) |
| Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for |
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-24 15:05:41 |
Czytaj oryginał (ang.) |
| Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 |
CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 1, 2025, at 8:00 a.m. |
globenewswire.com |
2025-04-17 11:00:00 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for April 8th |
AFLYY, AGIO and ARLP have been added to the Zacks Rank #5 (Strong Sell) List on April 8, 2025. |
zacks.com |
2025-04-08 11:25:30 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for April 3rd |
AGIO, CHGG and EFX have been added to the Zacks Rank #5 (Strong Sell) List on April 3, 2025. |
zacks.com |
2025-04-03 08:55:30 |
Czytaj oryginał (ang.) |
| Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer |
CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the grant of inducement equity awards outside of the Company's 2023 Stock Incentive Plan to its newly appointed Chief Corporate Development & Strategy Officer, Krishnan Viswanadhan. The grants were approved by the Board of Directors effective as of March 5, 2025, as inducements material to Mr. Viswanadhan entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-03-05 19:52:00 |
Czytaj oryginał (ang.) |
| Agios to Present at Upcoming Investor Conferences |
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the following conferences: Leerink Global Healthcare Conference 2025: Fireside chat on Tuesday, March 11, 2025, at 10:50 a.m. |
globenewswire.com |
2025-03-04 09:00:00 |
Czytaj oryginał (ang.) |
| Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 |
CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025, at 10:30 a.m. ET. |
globenewswire.com |
2025-02-20 09:00:00 |
Czytaj oryginał (ang.) |
| Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues |
AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year. |
zacks.com |
2025-02-14 11:26:19 |
Czytaj oryginał (ang.) |
| Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript |
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Brian Goff - CEO Sarah Gheuens - CMO & Head OF R&D Tsveta Milanova - CCO Cecilia Jones - CFO Chris Taylor - VP, IR & Corporate Communications Conference Call Participants Eric Schmidt - Cantor Fitzgerald Divya Rao - TD Cowen Gregory Renza - RBC Capital Markets Greg Harrison - Scotiabank Chris Raymond - Piper Sandler Alec Stranahan - Bank of America Lydia Erdman - Goldman Sachs Tessa Romero - J.P. Morgan Operator Good morning, and welcome to Agios' fourth quarter 2024 conference call. |
seekingalpha.com |
2025-02-13 15:32:33 |
Czytaj oryginał (ang.) |
| Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates |
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.74 per share versus the Zacks Consensus Estimate of a loss of $1.73. This compares to loss of $1.72 per share a year ago. |
zacks.com |
2025-02-13 10:46:10 |
Czytaj oryginał (ang.) |
| Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights |
– Filed for Regulatory Approval of Mitapivat (PYRUKYND ® ) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates; PDUFA Goal Date of September 7, 2025 – |
globenewswire.com |
2025-02-13 08:31:00 |
Czytaj oryginał (ang.) |
| Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint |
– ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused – |
globenewswire.com |
2025-02-13 08:30:00 |
Czytaj oryginał (ang.) |
| Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 |
CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 13, 2025, at 8:00 a.m. |
globenewswire.com |
2025-02-06 09:00:00 |
Czytaj oryginał (ang.) |
| FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia |
If approved, AGIO's Pyrukynd will be the first oral therapy for all thalassemia subtypes. A final decision is expected by Sep. 7. |
zacks.com |
2025-01-09 11:20:30 |
Czytaj oryginał (ang.) |
| Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer |
BURLINGTON, Mass.--(BUSINESS WIRE)--Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently led corporate, portfolio and program strategy and business development a. |
businesswire.com |
2025-01-08 10:00:00 |
Czytaj oryginał (ang.) |
| Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 |
CAMBRIDGE, Mass., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 43rd Annual J.P. |
globenewswire.com |
2025-01-03 09:00:00 |
Czytaj oryginał (ang.) |
| European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease |
CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the European Commission has adopted a positive decision for the designation of mitapivat, an oral, small molecule PK activator, as an orphan medicinal product (OMP) for the treatment of sickle cell disease. Earlier, in November 2020, the U.S. Food and Drug Administration (FDA) also granted orphan drug designation to mitapivat for sickle cell disease. |
globenewswire.com |
2024-12-18 09:00:00 |
Czytaj oryginał (ang.) |
| Here's Why Agios Stock Plummeted More Than 20% on Monday |
The fall in AGIO stock comes after reports of an unexpected side effect linked to its sole-marketed drug Pyrukynd in thalassemia patients. |
zacks.com |
2024-12-10 13:50:29 |
Czytaj oryginał (ang.) |
| Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat |
– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – |
globenewswire.com |
2024-12-08 14:40:00 |
Czytaj oryginał (ang.) |
| 4 Medical Product Stocks to Buy From a Prospective Industry |
An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable factors. |
zacks.com |
2024-12-04 12:45:35 |
Czytaj oryginał (ang.) |
| Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year? |
Here is how Agios Pharmaceuticals (AGIO) and Twist Bioscience (TWST) have performed compared to their sector so far this year. |
zacks.com |
2024-11-26 12:41:16 |
Czytaj oryginał (ang.) |
| Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition |
– Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session – – Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b Trial-in-progress Update in Lower-risk Myelodysplastic Syndromes will be Presented and Published – – Live and Webcast Investor Event with Agios Leadership and Medical Experts will be Hosted Onsite on Monday, December 9 – CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on mitapivat and tebapivat (AG-946), the company's PK activators, will be featured in oral and poster presentations during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California from December 7-10, 2024. |
globenewswire.com |
2024-11-05 11:05:00 |
Czytaj oryginał (ang.) |
| AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down |
Agios' third-quarter 2024 earnings miss estimates while revenues match the same. Shares fall. |
zacks.com |
2024-11-01 13:50:16 |
Czytaj oryginał (ang.) |
| Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript |
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Brian Goff - Chief Executive Officer Sarah Gheuens - Chief Medical Officer and Head, R&D Tsveta Milanova - Chief Commercial Officer Cecilia Jones - Chief Financial Officer Conference Call Participants Greg Harrison - Scotiabank Alex Nackenoff - Raymond James Greg Renza - RBC Capital Markets Eric Schmidt - Cantor Fitzgerald Chris Raymond - Piper Sandler Tessa Romero - JPMorgan Divya Rao - TD Cowen Alec Stranahan - Bank of America Lydia Erdman - Goldman Sachs Andrew Berens - Leerink Partners Operator Good morning, and welcome to Agios' Third Quarter 2024 Conference Call. [Operator Instructions] Please be advised that today's call is being recorded at Agios' request. |
seekingalpha.com |
2024-10-31 16:16:09 |
Czytaj oryginał (ang.) |
| Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates |
Agios Pharmaceuticals (AGIO) came out with quarterly earnings of $4.20 per share, missing the Zacks Consensus Estimate of $16.69 per share. This compares to loss of $1.64 per share a year ago. |
zacks.com |
2024-10-31 10:46:19 |
Czytaj oryginał (ang.) |
| Agios Reports Business Highlights and Third Quarter 2024 Financial Results |
– Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 – – Received $1.1 Billion in Payments from Royalty Pharma and Servier, Following FDA Approval of Vorasidenib – – Commenced Enrollment of the Phase 2b Study of Tebapivat in Lower-Risk Myelodysplastic Syndromes (LR-MDS); Granted FDA Orphan Drug Designation for Treatment of MDS – – PYRUKYND® (Mitapivat) Net Revenue of $9.0 Million in Q3; Cash, Cash Equivalents and Marketable Securities of $1.7 Billion as of September 30, 2024 – CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported business highlights and financial results for the third quarter ended September 30, 2024. |
globenewswire.com |
2024-10-31 08:30:00 |
Czytaj oryginał (ang.) |
| Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024 |
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, October 31, 2024, at 8:00 a.m. ET to report its third quarter 2024 financial results and business highlights. |
globenewswire.com |
2024-10-17 11:00:00 |
Czytaj oryginał (ang.) |
| FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer |
The FDA bestows an orphan drug designation to Agios' PK activator, tebapivat, for treating myelodysplastic syndromes. |
zacks.com |
2024-09-12 16:35:25 |
Czytaj oryginał (ang.) |
| Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS) |
CAMBRIDGE, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's novel pyruvate kinase (PK) activator tebapivat (AG-946) for the treatment of myelodysplastic syndromes (MDS). |
globenewswire.com |
2024-09-11 11:00:00 |
Czytaj oryginał (ang.) |
| Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024 |
CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 a.m. |
globenewswire.com |
2024-09-05 11:00:00 |
Czytaj oryginał (ang.) |
| Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment |
Agios' Pyrukynd is FDA-approved for pyruvate kinase deficiency but generated modest sales of $8.6 million in Q2 2024. Mitapivat shows promise in treating SCD and thalassemia, with ongoing Phase 3 trials showing positive results for hemoglobin improvement. Expanding Pyrukynd's label to include pediatric and thalassemia indications is crucial, with regulatory filings expected by 2025. |
seekingalpha.com |
2024-08-27 14:18:20 |
Czytaj oryginał (ang.) |
| Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib |
– Agios Expects to Receive $905 Million Payment from Royalty Pharma and $200 Million Payment from Servier in Q3 2024; Payments Increase Agios' Pro-Forma Cash Position as of June 30, 2024, to $1.7 Billion – – Strong Cash Position to Enable Agios to Prepare for Potential PYRUKYND® (Mitapivat) Launches in Thalassemia in 2025 and Sickle Cell Disease in 2026 and Drive Pipeline Progress – CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the Company will receive a total of $1.1 billion in milestone payments following the U.S. Food and Drug Administration (FDA) approval of vorasidenib for adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery, including biopsy, sub-total resection or gross total resection. |
globenewswire.com |
2024-08-06 21:50:00 |
Czytaj oryginał (ang.) |
| AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal |
Agios' (AGIO) second-quarter 2024 numbers miss estimates. Its sole-marketed drug fails to meet the primary endpoint of a late-stage label expansion study in pediatric patients with PK deficiency. |
zacks.com |
2024-08-02 15:46:12 |
Czytaj oryginał (ang.) |
| Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides |
On Thursday, Agios Pharmaceuticals Inc AGIO released topline results from the global Phase 3 ACTIVATE-KidsT study of mitapivat in children aged 1 to |
benzinga.com |
2024-08-01 17:42:10 |
Czytaj oryginał (ang.) |
| Agios Pharmaceuticals, Inc. (AGIO) Q2 2024 Earnings Call Transcript |
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2024 Results Conference Call August 1, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Brian Goff - Chief Executive Officer Sarah Gheuens - Chief Medical Officer and Head, R&D Tsveta Milanova - Chief Commercial Officer Cecilia Jones - Chief Financial Officer Conference Call Participants Eric Schmidt - Cantor Christopher Raymond - Piper Sandler Gregory Renza - RBC Capital Markets Divya Rao - TD Cowen Tess Romero - JP Morgan Alec Stranahan - Bank of America Operator Good morning, and welcome to Agios' Second Quarter 2024 Conference Call. [Operator Instructions]. |
seekingalpha.com |
2024-08-01 16:11:08 |
Czytaj oryginał (ang.) |